Table 2.
Completed clinical trials of anti-PD-1
| mAb alone/combination | Phase | Setting | Result | NCT |
|---|---|---|---|---|
| Nivolumab | I | mCRPC | No response | NCT00730639 |
| Nivolumab + Ipilimumab | II | AR-V7+ mCRPC |
PSA50 Response: 13% (2/15) ORR: 25% Durable PFS: 20% |
NCT02601014 |
| Nivolumab + cabozantinib | I | mCRPC | Well tolerated | NCT02496208 |
| Pembrolizumab + enzalutamide | II |
Enzalutamide-resistant PCa |
PSA Response: 20% | NCT02312557 |
| Pembrolizumab | Ib | mCRPC |
ORR: 13% Response duration: 59 weeks Median OS: 8 months |
NCT02054806 |
| Pembrolizumab | II | PCa with somatic MMR mutation | ORR: 100% (1/1) | NCT01876511 |